Scholar Rock De-risks Apitegromab Launch Path Following FDA Resolution

Scholar Rock (SRRK) has successfully navigated key regulatory hurdles, clearing the path for the commercial launch of its lead drug candidate, apitegromab. The company announced that manufacturing concerns previously raised by the FDA regarding Catalent's facility have been resolved. This development significantly reduces regulatory risks and stabilizes the timeline for the drug's anticipated US launch in 2026. On the financial front, Scholar Rock has fortified its balance sheet with a $550 million non-dilutive debt facility and a cash reserve of $370 million. This robust capital position minimizes the immediate need for dilutive equity financing as the company transitions toward commercial execution. Analysts view the combination of manufacturing clarity and financial stability as a significant positive catalyst for the biotech firm.

Sources:seekingalpha.cominsights.citeline.comzoominfo.comminichart.com.sg